Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bart Claes

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Thorax|December 10, 2009
Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding geneWim Janssens, Roger Bouillon, Bart Claes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2009
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancerHans Prenen, Jef De Schutter, Bart Jacobs, et al.
American Journal of Clinical Pathology|September 20, 2021
Evaluation of Cytologic Sample Preparations for Compatibility With Nucleic Acid AnalysisLaure Sorber, Bart Claes, Karen Zwaenepoel, et al.
Journal of the National Cancer Institute|June 7, 2013
Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancerSherene Loi, Stefan Michiels, Diether Lambrechts, et al.
The New England Journal of Medicine|July 24, 2009
Thrombomodulin mutations in atypical hemolytic-uremic syndromeMieke Delvaeye, Marina Noris, Astrid De Vriese, et al.
ESMO Open|October 12, 2017
Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practiceJames L Sherwood, Helen Brown, Alessandro Rettino, et al.
The Lancet. Oncology|May 22, 2012
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trialsDiether Lambrechts, Bart Claes, Paul Delmar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 7, 2013
Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximabChristopher G Smith, David Fisher, Bart Claes, et al.
Gynecologic Oncology|December 11, 2012
High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinomaDiego A Garcia-Dios, Diether Lambrechts, Lieve Coenegrachts, et al.
Plos One|August 1, 2012
Comprehensive mutation analysis in colorectal flat adenomasQuirinus J M Voorham, Beatriz Carvalho, Angela J Spiertz, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Thorax|December 10, 2009
Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding geneWim Janssens, Roger Bouillon, Bart Claes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2009
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancerHans Prenen, Jef De Schutter, Bart Jacobs, et al.
American Journal of Clinical Pathology|September 20, 2021
Evaluation of Cytologic Sample Preparations for Compatibility With Nucleic Acid AnalysisLaure Sorber, Bart Claes, Karen Zwaenepoel, et al.
Journal of the National Cancer Institute|June 7, 2013
Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancerSherene Loi, Stefan Michiels, Diether Lambrechts, et al.
The New England Journal of Medicine|July 24, 2009
Thrombomodulin mutations in atypical hemolytic-uremic syndromeMieke Delvaeye, Marina Noris, Astrid De Vriese, et al.
ESMO Open|October 12, 2017
Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practiceJames L Sherwood, Helen Brown, Alessandro Rettino, et al.
The Lancet. Oncology|May 22, 2012
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trialsDiether Lambrechts, Bart Claes, Paul Delmar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 7, 2013
Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximabChristopher G Smith, David Fisher, Bart Claes, et al.
Gynecologic Oncology|December 11, 2012
High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinomaDiego A Garcia-Dios, Diether Lambrechts, Lieve Coenegrachts, et al.
Plos One|August 1, 2012
Comprehensive mutation analysis in colorectal flat adenomasQuirinus J M Voorham, Beatriz Carvalho, Angela J Spiertz, et al.
Pageof 2